GLP-1 receptor agonists (GLP-1 RAs) are revolutionizing glycemic control for patients with type 2 diabetes (T2D), but with rising clinical complexity and diverse patient needs, a one-size-fits-all approach is insufficient. While every currently available GLP-1 RA is indicated for blood …
A major hurdle in managing type 2 diabetes (T2D) is a widespread gap in clinician awareness around the powerful, far-reaching benefits of GLP-1 receptor agonists (GLP-1 RAs). These innovative therapies help reduce the burden of cardiovascular, kidney, and metabolic (CKM) …
Unlike many other cancers, rates of anal cancer and death due to anal cancer are rising in the United States. The increasing incidence is primarily seen in high-risk populations including men who have sex with men (MSM) and people living …
New diagnoses of HIV continue at a rapid pace despite the availability of preventative options. This is particularly true among underserved populations, including racial and ethnic minorities, who often go undiagnosed or underdiagnosed due to disparities in access to care. …
Recent advances in the treatment of hemophilia, a genetically X-linked bleeding disorder, include non-factor prophylactic therapies such as factor VIII mimetics, anti-tissue factor pathway inhibitors (anti-TFPIs) and small interfering RNA (siRNA) treatments. Health care professionals (HCPs) treating patients with hemophilia …
Recent advances in the treatment of hemophilia, a genetically X-linked bleeding disorder, include non-factor prophylactic therapies such as factor VIII mimetics, anti-tissue factor pathway inhibitors (anti-TFPIs) and small interfering RNA (siRNA) treatments. Health care professionals (HCPs) treating patients with hemophilia …
